Daiwa Securities Group Inc. Reduces Holdings in Repligen Co. (NASDAQ:RGEN)

Daiwa Securities Group Inc. cut its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 27.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,580 shares of the biotechnology company's stock after selling 6,905 shares during the quarter. Daiwa Securities Group Inc.'s holdings in Repligen were worth $2,765,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of RGEN. Toronto Dominion Bank lifted its position in Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock valued at $656,000 after acquiring an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC lifted its holdings in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after purchasing an additional 105 shares during the last quarter. Diversified Trust Co grew its stake in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after buying an additional 106 shares during the last quarter. Finally, CWM LLC increased its position in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after buying an additional 114 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

NASDAQ:RGEN traded up $3.25 during trading hours on Thursday, hitting $149.99. 452,661 shares of the stock were exchanged, compared to its average volume of 666,697. The firm's fifty day moving average price is $140.74 and its 200 day moving average price is $142.89. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a market cap of $8.40 billion, a P/E ratio of -405.37, a P/E/G ratio of 4.40 and a beta of 0.96. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the company posted $0.23 earnings per share. The business's revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.